AOD-9604 Manufacturer Copay Program: What Actually Exists (and How to Lower Your Cost)

Why There Is No AOD-9604 Manufacturer Copay Card

A manufacturer copay program requires an FDA-approved branded product. AOD-9604, the synthetic C-terminal fragment spanning amino acids 176 through 191 of human growth hormone, has never received FDA approval for any indication in the United States. No pharmaceutical company holds an NDA or BLA for this peptide. That means no branded manufacturer exists to sponsor a copay card, coupon, or patient assistance program.

This is a different situation from drugs like semaglutide, where Novo Nordisk operates the Savings Offer program for Wegovy and Ozempic. AOD-9604 occupies a regulatory gray zone. The FDA has included it on the bulk drug substances list that 503A and 503B pharmacies may use for compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies produce it on a per-prescription basis. Each pharmacy sets its own price independently.

The practical result: there is no central manufacturer to call, no copay card to download, and no patient assistance foundation to apply to. Every dollar of AOD-9604 cost comes out of pocket. Programs change frequently, so always verify pricing directly with the dispensing pharmacy before committing to treatment.

What AOD-9604 Actually Costs in 2026

The average compounded price for a 30-day supply of AOD-9604 falls between $150 and $250, though the range stretches wider depending on concentration, volume, and pharmacy markup. Some clinics charge $300 or more when they bundle the peptide with a consultation fee.

Several variables drive price variation. Dose matters: a patient prescribed 250 mcg daily will use roughly half the peptide volume of someone on 500 mcg daily. Formulation matters too. Subcutaneous injectable vials (typically 5 mg per vial reconstituted with bacteriostatic water) differ in cost from oral lozenges or sublingual troches, which some pharmacies offer despite weaker pharmacokinetic data supporting non-injectable routes.

A 2005 double-blind, placebo-controlled trial by Heffernan et al. (N=300) examined oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, 20 mg, and 50 mg daily for 12 weeks and found no significant weight loss versus placebo in obese adults [1]. That negative oral bioavailability data is one reason most prescribers favor injectable formulations. Patients paying for an oral form should understand they may be paying for a less-studied route.

Geographic location also shifts price. Pharmacies in states with higher compounding oversight costs (California, New York) tend to charge $20 to $50 more per vial than pharmacies in Texas or Florida. Shipping fees add $10 to $25 for cold-chain overnight delivery, which is required for reconstituted peptides.

The Insurance Reality for AOD-9604

No commercial health insurer, Medicare Part D plan, or Medicaid program covers AOD-9604. This is not a coverage gap that appeals or prior authorizations can fix. The reason is structural.

Insurance formularies list FDA-approved drugs by their National Drug Code (NDC). Compounded preparations do not carry standard NDCs in the same way. Even when a compounder assigns a facility-level NDC, payers reject claims for products without an FDA-approved indication. The Endocrine Society's 2019 position statement on growth hormone does not mention AOD-9604 at all, reflecting its absence from clinical endocrinology guidelines. Without guideline backing or FDA approval, insurers have no basis to authorize coverage.

Some patients attempt to submit AOD-9604 costs to Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs). The IRS requires HSA/FSA-eligible expenses to treat a diagnosed medical condition and to be prescribed by a licensed provider. If a physician prescribes AOD-9604 for a specific diagnosis (obesity, lipodystrophy), the expense may qualify. Consult a tax advisor before assuming eligibility, because the IRS has not published specific guidance on compounded peptides.

Dr. Karl Nadolsky, an endocrinologist and diplomate of the American Board of Obesity Medicine, has stated: "Patients need to understand that 'not covered' doesn't always mean 'not legitimate,' but it does mean you bear 100% of the financial risk. Budget accordingly."

How to Lower Your AOD-9604 Cost

Since no copay card exists, cost reduction depends on direct negotiation and smart purchasing. These strategies produce real savings.

Compare at least three compounding pharmacies. Pricing varies by 40% or more between pharmacies for the same concentration and volume. Request quotes from both 503A (patient-specific) and 503B (outsourcing facility) pharmacies. 503B facilities like Help Pharmacy and Hallandale Pharmacy often offer lower per-unit costs because they compound in larger batches under FDA 503B outsourcing facility regulations.

Ask about multi-vial discounts. Many pharmacies reduce the per-vial price by 10% to 20% when you order a 60- or 90-day supply. A single 5 mg vial at $200 might drop to $170 per vial when ordering three at once. Cold-chain shipping is also amortized across the larger order.

Use telehealth platforms that bundle prescriber visits with pharmacy pricing. Several telehealth peptide clinics negotiate volume pricing with partner pharmacies and pass part of the savings to patients. Monthly all-inclusive costs (visit plus peptide) through these platforms often land between $175 and $225, which can be less than a separate clinic visit ($75 to $150) plus a standalone pharmacy purchase.

Check for loyalty or subscription programs at the dispensing pharmacy. Some compounders offer auto-refill discounts of 5% to 15%. These are not manufacturer programs. They are pharmacy-level incentives to retain recurring customers.

Avoid buying AOD-9604 from research chemical vendors. Products sold "for research purposes only" are not manufactured under cGMP or USP 797/800 standards, are not prescribed by a licensed clinician, and carry unknown purity and sterility risks. The FDA has issued warnings about unapproved peptide products sold online. Any apparent savings vanish if the product is contaminated or underdosed.

AOD-9604 Versus Other Fat-Loss Peptides: Cost Comparison

Understanding AOD-9604's price in context helps determine whether it represents good value for the clinical effect.

Semaglutide 2.4 mg (Wegovy) carries a list price of approximately $1,349 per month, though manufacturer savings cards can reduce this to $0 to $500 for commercially insured patients. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% for placebo [2]. No comparable large-scale RCT demonstrates similar efficacy for AOD-9604.

Tirzepatide (Zepbound) lists at roughly $1,059 per month. The SURMOUNT-1 trial (N=2,539) showed 22.5% weight loss with the 15 mg dose at 72 weeks [3]. Again, AOD-9604 lacks any phase III trial showing weight-loss results of this magnitude.

Compounded semaglutide from 503B pharmacies (while still available under the FDA's current shortage framework) costs $150 to $400 per month, putting it in the same price bracket as AOD-9604 but with substantially more clinical evidence behind it.

Tesamorelin (Egrifta SV), FDA-approved for HIV-associated lipodystrophy, costs roughly $1,500 per month at list price. A 26-week trial by Falutz et al. (N=412) showed a 15.4% reduction in visceral adipose tissue versus 5.2% for placebo [4].

AOD-9604 at $150 to $250 per month is among the least expensive injectable peptides marketed for body composition. The trade-off is weaker clinical evidence. A 2004 study by Stier et al. found that the HGH fragment 176-191 stimulated lipolysis in adipose tissue samples in vitro at rates comparable to full-length hGH without affecting IGF-1 or glucose [5]. But in vitro lipolysis does not automatically translate to meaningful fat loss in human subjects, as the failed oral trial demonstrated.

What the FDA Says About AOD-9604

The FDA's regulatory position on AOD-9604 is nuanced and has shifted over time. The peptide appears on the FDA's list of bulk drug substances for which there is a clinical need under section 503B. This listing permits outsourcing facilities to compound it without individual patient prescriptions, provided they meet current good manufacturing practice (cGMP) requirements.

For 503A pharmacies, AOD-9604 can be compounded if the prescriber writes a patient-specific prescription and the pharmacy meets state board of pharmacy requirements plus the conditions of section 503A. This is the legal pathway most patients use.

The FDA has not approved AOD-9604 for any therapeutic indication. There is no approved labeling, no official dosing guidance, and no required medication guide. The Therapeutic Goods Administration (TGA) of Australia evaluated AOD-9604 in the mid-2000s when Metabolic Pharmaceuticals pursued it as an anti-obesity drug. After the oral efficacy trials failed to meet endpoints, development was abandoned and no application was filed with the FDA.

Prescribers who order AOD-9604 do so on an off-label, evidence-informed basis. The clinical responsibility sits with the prescribing provider.

Verifying Your Compounding Pharmacy's Legitimacy

Because no manufacturer oversees quality centrally, patients must vet their compounding pharmacy independently. This due diligence protects both your health and your wallet.

Confirm the pharmacy holds a valid state license by checking your state board of pharmacy's online verification tool. For 503B outsourcing facilities, verify FDA registration on the FDA outsourcing facility registry. Ask whether the pharmacy holds PCAB (Pharmacy Compounding Accreditation Board) accreditation, which requires adherence to USP 797 and USP 800 standards.

Request a Certificate of Analysis (CoA) for your specific batch. A legitimate pharmacy will provide third-party testing results showing peptide purity (target: greater than or equal to 98%), endotoxin levels, and sterility. If a pharmacy refuses to share a CoA or claims testing is proprietary, find a different pharmacy.

Dr. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, has noted: "A quality compounder welcomes transparency. If you're paying $200 a month for a peptide with no FDA approval, you have every right to see the lab data."

Review the pharmacy's FDA inspection history through the FDA's database of Form 483 observations. Multiple unresolved 483 findings indicate quality-system failures.

When AOD-9604 May Not Be Worth the Cost

Spending $150 to $250 per month on any therapy requires honest assessment of expected benefit. For AOD-9604, the evidence base is thin enough that some patients will get better value elsewhere.

If your primary goal is weight loss exceeding 10% of body weight, the data favor GLP-1 receptor agonists. The STEP-1 trial demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks [2], and SURMOUNT-1 showed 22.5% with tirzepatide 15 mg at 72 weeks [3]. AOD-9604 has no completed phase III trial showing any specific percentage of weight loss in humans.

If your goal is modest body-composition improvement and you prefer a peptide with a lower side-effect profile than GLP-1 agonists (no nausea, no gastroparesis risk), AOD-9604 may have a role. But recognize that you are paying for biological plausibility supported by preclinical and early-phase data, not for a clinically validated outcome.

If cost is your primary barrier to any peptide therapy, structured lifestyle intervention remains the most cost-effective approach. A meta-analysis by Johns et al. published in Obesity Reviews (2014) found that behavioral weight management programs produced 3 to 5 kg of sustained weight loss at 12 months, which costs nothing beyond time and possibly a dietitian visit covered by insurance [6].

Steps to Start AOD-9604 at the Lowest Possible Cost

Follow this sequence to minimize your out-of-pocket spending:

1. Get a prescription from a licensed provider (MD, DO, NP, or PA in your state). Telehealth peptide clinics typically charge $50 to $150 for an initial consultation.
2. Request the prescription be sent to at least two compounding pharmacies. Ask each for a quote on a 30-day and 90-day supply of 5 mg vials.
3. Confirm the pharmacy's state license and, for 503B facilities, FDA registration status.
4. Ask about auto-refill or subscription discounts before placing your first order.
5. Request a Certificate of Analysis for your batch upon delivery.
6. Schedule follow-up labs (fasting glucose, IGF-1, lipid panel) at 8 to 12 weeks to assess whether the peptide is producing measurable changes worth continuing.

If 12-week labs show no meaningful change in body composition or metabolic markers, discontinue and redirect the $450 to $750 spent toward an evidence-based alternative. Cost-effectiveness depends on results. No copay card in the world fixes a therapy that is not working.